Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Processa Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Processa Pharmaceuticals's regulatory disclosures and financial reporting.
Processa Pharmaceuticals director Justin W. Yorke reported a routine equity compensation event. On June 26, 2026, he exercised a time-based service restricted stock award, converting 203 restricted shares into 203 shares of common stock at $0.00 per share.
After the transaction, Yorke holds 353 common shares directly, plus 496 common shares held indirectly through a directed trust IRA and 1,250 common shares held indirectly via Richland Fund, LLC. He also continues to hold 5,249 restricted stock units directly.
Processa Pharmaceuticals director Geraldine Pannu reported a routine equity compensation event. She exercised a derivative award relating to 203 shares of Common Stock on June 26, 2026, at a stated exercise price of $0.00 per share, tied to a time-based service award.
Following the transaction, her direct holdings of Common Stock increased to 2,391 shares. The related Restricted Stock position, which served as the derivative security, showed 5,249 units following the exercise. The filing characterizes this as an exercise or conversion of a derivative security, reflecting compensation rather than an open-market trade.
Processa Pharmaceuticals director Neal James R reported a compensation-related share vesting. On June 26, 2026, he exercised a time-based service award, converting 203 shares of restricted stock into 203 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 1,021 shares of common stock and 5,249 shares of restricted stock. The filing shows an exercise of a derivative security rather than any open-market purchase or sale of Processa Pharmaceuticals stock.
Processa Pharmaceuticals director Baluch Khoso reported a small equity compensation event. On June 26, 2026, Khoso exercised a time-based service award, converting 203 shares of Restricted Stock into 203 shares of Common Stock at an exercise price of $0.00 per share.
After the transaction, Khoso directly held 2,528 shares of Common Stock and 5,249 shares of Restricted Stock, reflecting a routine distribution of equity granted for service rather than an open-market purchase or sale.
Processa Pharmaceuticals is holding its 2026 annual shareholder meeting on July 30, 2026 in Kennesaw, Georgia. Shareholders will vote on electing six directors, increasing the 2019 Omnibus Incentive Plan share reserve by 200,000 shares, ratifying Cherry Bekaert as auditor for 2026, and approving 2025 executive pay on an advisory basis.
Shareholders of record as of June 1, 2026, when 2,768,032 common shares were outstanding, are entitled to vote in person or by proxy, including online and telephone options.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of common stock. He bought 2,067 shares on June 15, 2026 at $2.22 per share, bringing his directly held position to 19,198 shares of Processa Pharmaceuticals common stock.
In addition to these directly owned shares, he is also reported as having indirect ownership of 1,009 shares through CorLyst, LLC, 432 shares through Family Entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. On this transaction date, he bought 2,654 shares of common stock at a price of $2.22 per share. Following the purchase, his direct holdings increased to 13,412 shares of common stock.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,465 shares of Common Stock at $2.22 per share. Following this trade, his directly held Common Stock position increased to 12,435 shares.
Ng also reports indirect ownership of Common Stock, including 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account labeled George Ng IRRA FOB George Ng.
Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin bought 1,831 shares of Common Stock in an open-market transaction at $2.22 per share. Following this purchase, he directly owns 11,007 shares and reports 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals, Inc. Chief Administrative Officer Wendy Guy reported an open-market purchase of 2,118 shares of common stock at $2.22 per share on June 15, 2026. After this transaction, Guy directly holds 11,958 common shares and has an additional 333 shares reported as indirectly owned through CorLyst, LLC.